| Safety of botulinum toxin type A in children younger than 2 years. | |
| | |
MedLine Citation:
|
PMID: 19036619 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Botulinum toxin type A (BoNT-A) has been used in many indications and is licensed for the treatment of spasticity in children older than 2 years. However, there are few reports of BoNT-A treatment in patients younger than 2 years of age. AIMS: To review retrospectively the safety data from all infants treated with botulinum toxin type A (BoNT-A) before 2 years of age in a paediatric neurology unit. METHODS: There were 74 infants: 28 received the first dose before 1 year of age, and 46 between the ages of 1 and 2 years. RESULTS: In the first year of life, the most frequent indication was obstetric brachial palsy (OBP) (71.4% of cases) and in the second year, cerebral palsy (CP) (73.9%). Both Botox and Dysport, the two commercially-available BoNT-A products in Spain, were used. The average starting dose by session was 6.55 U/kg body weight Botox in infants in their first year of life, and 8.4 U/kg body weight Botox and 21.1 U/kg body weight Dysport in the second year of life. Only 3.6% of cases treated in the first year and 6.5% of those treated in the second experienced adverse events (AEs), which consisted of mild weakness or tiredness lasting 1-4 days. CONCLUSIONS: BoNT-A has a good safety profile in infants younger than 2 years old. AEs are similar to those found in older children. |
| | |
Authors:
|
Samuel Ignacio Pascual-Pascual; Ignacio Pascual-Castroviejo |
Related Documents
:
|
17146199 - Periventricular leukomalacia with late-onset circulatory dysfunction of premature infan... 3900799 - Periventricular leukomalacia: a correlation study between real-time ultrasound and auto... 10735459 - The role of cortical evoked responses in predicting neuromotor outcome in very preterm ... 976279 - Analysis of etiologic factors in cerebral palsy with severe mental retardation. i. anal... 9521949 - Trends in mortality and cerebral palsy in a geographically based cohort of very low bir... 9608889 - Magnesium sulfate and cerebral palsy in premature infants. 3752079 - Empirical validation of the essen-möller probability of paternity. 3821059 - An automatic feeder for infant rats. 20576369 - Intrauterine growth restriction in a low-income country: risk factors, adverse perinata... |
Publication Detail:
|
Type: Journal Article Date: 2008-11-25 |
Journal Detail:
|
Title: European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society Volume: 13 ISSN: 1532-2130 ISO Abbreviation: Eur. J. Paediatr. Neurol. Publication Date: 2009 Nov |
Date Detail:
|
Created Date: 2009-11-02 Completed Date: 2010-01-14 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9715169 Medline TA: Eur J Paediatr Neurol Country: England |
Other Details:
|
Languages: eng Pagination: 511-5 Citation Subset: IM |
Affiliation:
|
Pediatric Neurology Service, University Hospital La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain. ipascualp.hulp@salud.madrid.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Botulinum Toxin Type A
/
adverse effects*,
therapeutic use Cerebral Palsy / drug therapy Drug Toxicity / chemically induced* Humans Infant Neuromuscular Agents / adverse effects*, therapeutic use Paralysis, Obstetric / drug therapy Retrospective Studies Severity of Illness Index Spain Spasm / drug therapy Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Botulinum Toxin Type A; 0/Neuromuscular Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The predictive validity of general movements--a systematic review.
Next Document: Comparison between weight-based and IGF-I-based growth hormone (GH) dosing in the treatment of child...